To treat or not to treat? Cost-effectiveness of ace inhibitors in non-diabetic advanced renal disease-a dutch perspective

Kidney and Blood Pressure Research

Volumn 37, Issue 2-3, 2013, Pages 168-180

  Adarkwah, Charles Christian ^a,b   Gandjour, Afschin ^c   Akkerman, Maren ^d   Evers, Silvia ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c FRANKFURT SCHOOL OF FINANCE AND MANAGEMENT   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Advanced renal disease; Angiotensin converting enzyme inhibitors; Cost effectiveness; Decision modeling; Markov model

Indexed keywords

BENAZEPRIL; CREATININE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DISEASE COURSE; FEMALE; HEALTH CARE COST; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); NETHERLANDS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST UTILITY ANALYSIS; DRUG COST; END STAGE RENAL DISEASE; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HEALTH STATUS; KIDNEY DISEASE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RENAL REPLACEMENT THERAPY; STANDARDIZED MORTALITY RATIO;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CASE-CONTROL STUDIES; COST-BENEFIT ANALYSIS; CREATININE; DISEASE PROGRESSION; DRUG COSTS; FEMALE; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; NETHERLANDS; PROTEINURIA; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RENAL DIALYSIS;

EID: 84877866237     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000350142     Document Type: Review

References (61)

1. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW: Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006;354:131-140 (Pubitemid 43076710)
2. Dutch End-Stage Renal Disease Registry (Registratie Nierfunktievervanging Nederland) 2011. Available: https://www.renine.nl/page?id=home&lang=en. Accessed 18 October 2011.
3. Vegter S, Perna A, Hiddema W, Ruggenenti P, Remuzzi G, Navis G, Postma MJ: Cost effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism. Pharmacogenet Genomics 2009;19:695-703.
4. Peeters P, Rublee D, Just PM, Joseph A: Analysis and interpretation of cost data in dialysis: review of Western European literature. Health Policy 2000;54:209-227. (Pubitemid 32012610)
5. van Os N, Niessen LW, Bilo HJ, Casparie AF, van Hout BA: Diabetes nephropathy in the Netherlands: a cost effectiveness analysis of national clinical guidelines. Health Policy 2000;51:135-147. (Pubitemid 30138049)
6. de Wit GA, Ramsteijn PG, de Charro FT: Economic evaluation of end stage renal disease treatment. Health Policy 1998;44:215-232. (Pubitemid 28345184)
7. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939-945. (Pubitemid 26114159)
8. Ruggenenti P, Perna A, Benini R, Remuzzi G: Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. J Am Soc Nephrol 1998;9:2096-2101. (Pubitemid 28482158)
9. The GISEN Group: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-1863.
10. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN): A long-term, randomised clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. J Nephrol 1991; 3: 193-202.
11. Hogan TJ, Elliott WJ, Seto AH, Bakris GL: Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics 2002;20:37-47. (Pubitemid 34155214)
12. van Hout BA, Simeon GP, McDonnell J, Mann JF: Economic evaluation of benazepril in chronic renal insufficiency. Kidney Int 1997;63:S159-S162. (Pubitemid 28020458)
13. Bakris GL, Weir MR: Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000;160:685-693. (Pubitemid 30140419)
14. Moser M: Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists and calcium channel blocking agents: a review of potential benefits and possible adverse reactions. J Am Coll Cardiol 1997;29:1414-1421. (Pubitemid 27272431)
15. Brunner HR: ACE inhibitors in renal disease [Clinical Conference]. Kidney Int 1992;42:463-479.
16. Israili ZH, Hall WD: Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992;11:234-242.
17. Keane FW. Anderson S. Aurell M, de Zeeuw D, Narins RG, Povar G: Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions. Ann Intern Med 1989;111:503-516. (Pubitemid 19231308)
18. Brown NJ, Vaughan DE: Angiotensin-converting enzyme inhibitors. Circulation 1998;14:1411-1420. (Pubitemid 28182680)
19. Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincaid-Smith PS, Becker GJ: Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. Am J Kidney Dis 1996;27:489-495. (Pubitemid 26106596)
20. Adarkwah CC, Gandjour A: Cost-effectiveness of angiotensin-converting enzyme inhibitors in non-diabetic advanced renal disease. Expert Rev Pharmacoecon Outcomes Res 2011;11:215-223.
21. Ruggenenti P, Pagano E, Tammuzzo L, Benini R, Garattini L, Remuzzi G: Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney Int 2001;59:286-294. (Pubitemid 32055237)
22. Schädlich PK, Brecht JG, Brunetti M, Pagano E, Rangoonwala B, Huppertz E: Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics 2001;19:497-512. (Pubitemid 32488751)
23. Adarkwah CC, Gandjour A: Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany. Int J Technol Assess Health Care 2010;26:62-70.
24. Adarkwah CC, Gandjour A, Akkerman M, Evers SM: Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of diabetic nephropathy in the Netherlands-a Markov model. PLoS ONE 2011;6:e26139.
25. Gold MR, Siegel JE, Russell LB, Weinstein MC (eds.) Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
26. Golan L, Birkmeyer JD, Welch HG: The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999;131:660-667. (Pubitemid 29517951)
27. Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S: Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med 2005;143:89-99.
28. Terajima T, Yamagata S, Satoh N, Ueda S: Meta-analysis: effect of ACE-inhibitors on outcomes in patients with renal insufficiency. Pharm Ther 2003;28:98-112. (Pubitemid 37499121)
29. Mantel N, Haenszel W: Statistical aspects of the analysis of data from the retrospective analysis of disease. J Natl Cancer Inst 1959;22:719-748.
30. Kuntz KM, Weinstein MC: Modelling in economic evaluation. In: Drummond M, McGuire A, eds. Economic evaluation in health care: merging theory with practice. New York: Oxford University Press, 2005.
31. Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, Wiebe N, Tonelli M; Alberta Kidney Disease Network: Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010;303:423-429.
32. Hoerger TJ, Wittenborn JS, Segel JE, Burrows NR, Imai K, Eggers P, Pavkov ME, Jordan R, Hailpern SM, Schoolwerth AC, Williams DE; Centers for Disease Control and Prevention CKD Initiative: A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening. Am J Kidney Dis 2010;55:463-473.
33. Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, Martin PA: The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993;13:89-102. (Pubitemid 23113445)
34. Churchill DN, Torrance GW, Taylor DW, Barnes CC, Ludwin D, Shimizu A, Smith EK: Measurement of quality of life in end-stage renal disease: the time trade-off approach. Clin Invest Med 1987;10:14-20. (Pubitemid 17038999)
35. Arnesen T, Trommald M: Roughly right or precisely wrong? Systematic review of quality-of-life weights elicited with the time trade-off method. J Health Serv Res Policy 2004;9:43-50. (Pubitemid 38166453)
36. Bleichrodt H, Johannesson M: Standard gamble, time trade-off and rating scale: experimental results on the ranking properties of QALYs. J Health Econ 1997;16:155-175. (Pubitemid 27293319)
37. Dolan P, Gudex C, Kind P, Williams A: Valuing health states: a comparison of methods. J Health Econ 1995;15:209-231.
38. Dale PL, Hutton J, Elgazzar H: Utility of health states in chronic kidney disease: a structured review of the literature. Curr Med Res Opin 2008;24:193-206. (Pubitemid 351160252)
39. Statline-Central Bureau for Statistics: Consumer prices; price index Available: http://statline.cbs.nl/StatWeb/publication/?DM=SLEN&PA= 71311eng&D1=4&D2=0&D3=12,25,38,51,64,77,90,103,116,129,142,155,168, 181,194&LA=EN&HDR=T,G1&STB=G2&VW=T. Accessed 18 October 2011.
40. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-S266.
41. Royal College of Physicians: Chronic kidney disease-national clinical guideline for early identification and management in adults in primary and secondary care. London: Royal College of Physicians of London (2008).
42. College voor Zorgverzekeringen (CVZ). Dutch guidelines for pharmacoeconomic research; Diemen: CVZ. Available: http://www.ispor.org/ peguidelines/source/PE-guidelines-english-Netherlands.pdf. Accessed 18 October 2011.
43. Farmacotherapeutisch kompas 2010, Medisch Farmaceutische Voorlichting, Uitgave van de Commissie Farmaceutische Hulp (CFH), van het College voor zorgverzekering (CVZ).
44. College Voor Zorgverzekeringen (CVZ). GIPeilingen 2009. Ontwikkelingen genees-en hulpmiddelengebruik. Available: http://www.cvz.nl/binaries/live/ cvzinternet/hst-content/nl/documenten/gipeilingen/gip2009.pdf. Accessed 18 October 2011.
45. Nederlandse Zorgautoriteit, Rapport Inkoopvordelen en praktijkkosten apotheekhoudenden 2009, 2010 en 2011, gevolgen voor flexibel tarief 2011, Nov. 2010, p. 52.
46. Nebel M: Costs of renal replacement therapies in Germany in 1999. Nieren-und Hochdruckkrankheiten 2002;3:85-92. (Pubitemid 34250014)
47. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH: Handleiding voor kostenonderzoek. Methoden en standard kostprijzen voor economische evaluaties in de gezondheidszorg. Diemen: College voor zorgverzekeringen 2004.
48. Brouwer WB, Niessen LW, Postma MJ, Rutten FF: Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ 2005;331:446-448. (Pubitemid 41176388)
49. John JA, Whitaker D, Johnson DG: Statistical thinking in business (2nd ed.). Boca Raton, FL: Chapman & Hall/CRC, 2006.
50. Palmer AJ, Valentine WJ, Chen R, Mehin N, Gabriel S, Bregman B, Rodby RA: A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrol Dial Transplant 2008;23:1216-1223. (Pubitemid 351767535)
51. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983-1992. (Pubitemid 38296854)
52. Zidek W, Düsing R, Haller H, Middeke M, Paul M, Schmieder R, Schrader J; German Society of Hypertension: New recommendations of the German Hypertension League for the drug treatment of hypertension [in German]. Dtsch Med Wochenschr 2003;128:2468-2469. (Pubitemid 37494546)
53. Walma EP, Thomas S, Prins A, Grundmeyer HGLM, van der Laan JR, Wiersma TJ: NHG guideline hypertension, third revision (in Dutch). Huisarts Wet 2003;46:435-449.
54. Cardillo C, Mores N, Motolese M, Folli G: Effects of benazepril on stress testing blood pressure in essential hypertension. Am J Cardiol 1994;73:368-373. (Pubitemid 24068203)
55. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153. (Pubitemid 30051645)
56. Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA: Management of glomerular proteinuria: a commentary. J Am Soc Nephrol 2003;14:3217-3232. (Pubitemid 37509297)
57. Hebert LA, Wilmer WA, Falkenhain ME, Ladson-Wofford SE, Nahman NS Jr, Rovin BH: Renoprotection: one or many therapies? Kidney Int 2001;59:1211-1226.
58. Praga M: Slowing the progression of renal failure. Kidney Int 2002;80:S18-S22. (Pubitemid 34534153)
59. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-124. (Pubitemid 36092015)
60. Perna A, Ruggenenti P, Testa A, Spoto B, Benini R, Misefari V, Remuzzi G, Zoccali C: ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies. Kidney Int 2000;57:274-281 (Pubitemid 30227775)
61. Statline-Central Bureau for Statistics: Overlevingstafels (2010) Available: http://statline.cbs.nl/StatWeb/publication/?DM=SLNL&PA= 37360NED&D1=0&D2=a&D3=a&D4=l&HDR=G1, T&STB=G2 G3&CHARTTYPE=1&VW=T Accessed 18 October 2011.